Effect of Alirocumab on Mortality After Acute Coronary Syndromes
Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome.ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcome...
Elmentve itt :
| Szerzők: |
Steg Philippe Gabriel Szarek Michael Bhatt Deepak L Bittner Vera A Brégeault Marie-France Kollaborációs szervezet: ODYSSEY OUTCOMES Committees and Investigators Merkely Béla Péter Ungi Imre Horváth Iván |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2019
|
| Sorozat: | CIRCULATION
140 No. 2 |
| Tárgyszavak: | |
| doi: | 10.1161/CIRCULATIONAHA.118.038840 |
| mtmt: | 32665562 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/27010 |
Hasonló tételek
-
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Szerző: Schwartz Gregory G., et al.
Megjelent: (2018) -
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial /
Szerző: Jukema J. Wouter, et al.
Megjelent: (2019) -
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial /
Szerző: Ray Kausik K., et al.
Megjelent: (2019) -
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
Szerző: Roe Matthew T, et al.
Megjelent: (2019) -
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial
Szerző: Szarek Michael, et al.
Megjelent: (2019)